Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24622014 | 0.90 | KCNH2 (0.43) | DAOCOMTHCAR3HCAR2TP53 | |
| SCHEMBL24622013 | 0.83 | HPGD (0.44) | HCAR3HCAR2TP53MAPTSIGMAR1 | |
| SCHEMBL23957521 | 0.79 | NOS3 (0.50) | NOS3NOS1NOS2DAOHTR2A | |
| SCHEMBL1205832 | 0.78 | HCAR2 (0.41) | NOS2HCAR3HCAR2 | |
| SCHEMBL28209376 | 0.74 | KDM5A (0.47) | — | |
| SCHEMBL16231737 | 0.71 | DAO (0.54) | DAOHCAR2 | |
| SCHEMBL1204783 | 0.70 | HCAR2 (0.46) | HCAR3HCAR2TP53MAPT | |
| SCHEMBL27663556 | 0.70 | GAA (0.55) | HCAR2MAPT | |
| SCHEMBL18812733 | 0.69 | KMT2A (0.40) | HCAR3HCAR2 | |
| SCHEMBL12740609 | 0.69 | HCAR2 (0.48) | HCAR3HCAR2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793823-B2 | Compounds and pharmaceutical uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-10-24 | — | — | US | disclosed |
| US-11793823-B2 | Compounds and pharmaceutical uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-10-24 | — | — | US | disclosed |
| US-20220218730-A1 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218730-A1 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | HRH4, OR10J3, CYP3A5 | NOS3 2046/4885NOS1 3024/4885NOS2 3349/4885 |
| US-11793823-B2 | Compounds and pharmaceutical uses thereof | HRH4, OR10J3, CYP3A5 | NOS3 2046/4885NOS1 3024/4885NOS2 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.